Novan Inc
Total Current Liabilities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Novan Inc
Total Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Novan Inc
F:6LUA
Total Current Liabilities
$46.4m
CAGR 3-Years
53%
CAGR 5-Years
39%
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Total Current Liabilities
$50.9B
CAGR 3-Years
4%
CAGR 5-Years
6%
CAGR 10-Years
7%
Bristol-Myers Squibb Co
NYSE:BMY
Total Current Liabilities
$28.1B
CAGR 3-Years
14%
CAGR 5-Years
7%
CAGR 10-Years
15%
Pfizer Inc
NYSE:PFE
Total Current Liabilities
$36.6B
CAGR 3-Years
-6%
CAGR 5-Years
1%
CAGR 10-Years
3%
Merck & Co Inc
NYSE:MRK
Total Current Liabilities
$28.6B
CAGR 3-Years
8%
CAGR 5-Years
7%
CAGR 10-Years
5%
Eli Lilly and Co
NYSE:LLY
Total Current Liabilities
$40.1B
CAGR 3-Years
37%
CAGR 5-Years
27%
CAGR 10-Years
17%
No Stocks Found

Novan Inc
Glance View

Market Cap
1.3k EUR
Industry
Pharmaceuticals

Novan, Inc. is a biotechnology company, which engages in leveraging nitric oxide’s natural antiviral and immunomodulatory mechanisms of action to treat dermatological and oncovirus-mediated diseases. The company is headquartered in Durham, North Carolina and currently employs 29 full-time employees. The company went IPO on 2016-09-21. The firm is engaged in researching, developing and marketing products for skin diseases. The firm is focused on dermatology and anti-infective therapies. Its technology platform leverages nitric oxide’s naturally occurring anti-viral, anti-bacterial, anti-fungal, and immunomodulatory mechanisms of action to treat a range of diseases. The firm has clinical-stage dermatology and anti-infective drug candidates with multi-factorial (SB204), anti-viral (SB206), anti-fungal (SB208), and anti-inflammatory (SB414) mechanisms of action. The Company’s lead product candidate is SB206, which is a topical gel with anti-viral properties for the treatment of viral skin infections, with focus on molluscum contagiosum. The firm is exploring the potential of its NITRICIL technology as a potential treatment option for COVID-19, targeting the reduction of viral shedding and transmission.

6LUA Intrinsic Value
Not Available

See Also

What is Novan Inc's Total Current Liabilities?
Total Current Liabilities
46.4m USD

Based on the financial report for Dec 31, 2022, Novan Inc's Total Current Liabilities amounts to 46.4m USD.

What is Novan Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
39%

Over the last year, the Total Current Liabilities growth was 316%. The average annual Total Current Liabilities growth rates for Novan Inc have been 53% over the past three years , 39% over the past five years .

Back to Top